WHY IT MATTERS: Pregnant patients currently using cannabis for nausea or anxiety should understand that new preclinical evidence suggests THC exposure may alter placental biology in ways potentially linked to long-term neurodevelopmental risk in their children. CLINICAL OVERVIEW: Emerging preclinical research is examining how prenatal THC exposure may leave biological signatures in placental tissue that correspond to markers associated with schizophrenia risk. The placenta, long underappreciated as a clinically meaningful organ, appears to respond to cannabinoid exposure in ways that could influence fetal neurodevelopment through epigenetic and inflammatory pathways.
Teen Marijuana Use Doubles Chances of Future Psychotic Disorders, Study Finds
WHY IT MATTERS: Parents and adolescent patients should understand that the psychiatric risks associated with cannabis use before age 18 are biologically distinct from adult-onset use, and delaying initiation until adulthood is one of the most evidence-supported harm reduction strategies available. CLINICAL OVERVIEW: Research examining adolescent cannabis use has consistently identified a meaningful association between early initiation and elevated risk for psychotic spectrum disorders in adulthood, with the biological vulnerability of the developing adolescent brain playing a central role in this relationship. The endocannabinoid system undergoes significant maturation throughout adolescence, and exogenous cannabinoids introduced during this window appear to disrupt neurodevelopmental trajectories in ways that can have lasting psychiatric consequences.